Physicians may legally use a cleared device off-label in the practice of medicine. Manufacturers may not promote off-label use; doing so risks FDA enforcement and False Claims Act exposure when federal payment is involved. Companies can share some scientific information about unapproved uses under FDA guidance, with safeguards. Off-label promotion has led to some of the largest settlements in the industry.

Why it matters

Common in cardiology, orthopedics, and pediatrics where on-label populations are narrow. Manufacturers may share scientific information consistent with FDA guidance on responsive communications.

Common pitfalls

•Manufacturers can be penalized under the False Claims Act if off-label promotion leads to federal healthcare program reimbursement for non-covered uses.
•Assuming that the absence of a specific contraindication implies regulatory approval for an off-label application is a common pitfall.
•Failing to establish clear internal policies and training regarding permissible and impermissible communications about off-label use can lead to compliance breaches.
•Ignoring the ethical implications and potential patient harm associated with off-label use without sufficient scientific evidence can lead to serious consequences.
•Misinterpreting FDA guidance on firm-sponsored scientific and medical exchanges regarding unapproved uses can inadvertently lead to promotional activities.

Sources

AdvaMed Code of Ethics · AdvaMed
AHRMM - Healthcare Supply Chain · AHRMM
FDA scientific communications on unapproved uses of approved/cleared products (guidance pending implementation) · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.